DIHYDRALAZINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H10N6
Molecular Weight	190.2052
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NNC1=C2C=CC=CC2=C(NN)N=N1

InChI

InChIKey=VQKLRVZQQYVIJW-UHFFFAOYSA-N

InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)

HIDE SMILES / InChI

Molecular Formula	C8H10N6
Molecular Weight	190.2052
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Dihydralazine is a compound with antihypertensive properties and is in clinical trials, where is studied its effect on kidney function and hormones in healthy individuals.

Approval Year

Conditions

Conditions

Condition	Modality	Targets	Highest Phase	Product
High blood pressure 6	Primary		Not Provided 504	Unknown

PubMed

Show entries

Title	Date	PubMed
Effects of acute hypotension and hypertension on serum TSH concentrations in male rats.	1979 Oct	525373
Plasma volume and blood pressure regulation in hypertensive pregnancy.	2004 Jul	15201535
Flow injection chemiluminescence determination of dihydralazine sulphate based on permanganate oxidation sensitized by rhodamine B.	2004 Nov-Dec	15508136
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.	2004 Oct	15544435
Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain.	2004 Sep	15473668

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Patents

Sample Use Guides

In Vivo Use Guide

The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).

Route of Administration: Intravenous

In Vitro Use Guide

Unknown